[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605989":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":134,"collaborators":136,"id":139,"slug":140,"hasResults":141,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":10,"eligibilityCriteria":145,"healthyVolunteers":141,"sex":146,"minAge":147,"maxAge":10,"enrollmentInfo":148,"targetDuration":10,"studyType":151,"phases":10,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Resectable NSCLC Patients",null,"Receive Nivolumab in Combination with Chemotherapy",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Penny Medical Affairs Specialist, Clinical Pharmacology","CONTACT","886-2-8786-9750","penny.tsai@ono-pharma.com",[19,39,49,59,73,83,97,109,121],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Chang Gung Memorial Hospital Kaohsiung Branch","RECRUITING","Kaohsiung City","Taiwan","TW",{"type":26,"coordinates":27},"Point",[28,29],120.31333,22.61626,{"lat":29,"lon":28},[32,36],{"name":33,"role":15,"phone":34,"phoneExt":35,"email":10},"Yu-Fen Study Coordinator","+886-7-7317123","#2639",{"name":37,"role":38,"phone":10,"phoneExt":10,"email":10},"Chin-Chou Wang, Medicine","PRINCIPAL_INVESTIGATOR",{"facility":40,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":41,"geoPoint":43,"contacts":44},"Kaohsiung Medical University Chung-Ho Memorial Hospital",{"type":26,"coordinates":42},[28,29],{"lat":29,"lon":28},[45,47],{"name":46,"role":15,"phone":10,"phoneExt":10,"email":10},"Wan-Ming Study Coordinator",{"name":48,"role":38,"phone":10,"phoneExt":10,"email":10},"Jen-Yu Hung, Medicine",{"facility":50,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Kaohsiung Veterns General Hospital",{"type":26,"coordinates":52},[28,29],{"lat":29,"lon":28},[55,57],{"name":56,"role":15,"phone":10,"phoneExt":10,"email":10},"Shuen-Dury Yu",{"name":58,"role":38,"phone":10,"phoneExt":10,"email":10},"En-Kuei Tang, Medicine",{"facility":60,"status":21,"city":61,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"China Medical University Hospital","Taichung",{"type":26,"coordinates":63},[64,65],120.6839,24.1469,{"lat":65,"lon":64},[68,71],{"name":69,"role":15,"phone":70,"phoneExt":10,"email":10},"Mei-Hui Study Coordinator","+886-4-2206-5866",{"name":72,"role":38,"phone":10,"phoneExt":10,"email":10},"Te-Chun Hsia, Medicine",{"facility":74,"status":21,"city":61,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"Taichung Veterans General Hospital",{"type":26,"coordinates":76},[64,65],{"lat":65,"lon":64},[79,81],{"name":80,"role":15,"phone":10,"phoneExt":10,"email":10},"Shu-Jen Study Coordinator",{"name":82,"role":38,"phone":10,"phoneExt":10,"email":10},"Yen-Hsiang Huang, Medicine",{"facility":84,"status":21,"city":85,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Mackay Memorial Hospital Taipei Branch","Taipei",{"type":26,"coordinates":87},[88,89],121.52639,25.05306,{"lat":89,"lon":88},[92,95],{"name":93,"role":15,"phone":94,"phoneExt":10,"email":10},"Rainie Study Coordinator","+886-2-25433535",{"name":96,"role":38,"phone":10,"phoneExt":10,"email":10},"Jian Su, Medicine",{"facility":98,"status":21,"city":85,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":99,"geoPoint":101,"contacts":102},"National Taiwan University Hospital",{"type":26,"coordinates":100},[88,89],{"lat":89,"lon":88},[103,107],{"name":104,"role":15,"phone":105,"phoneExt":106,"email":10},"Jo-Yu Study Coordinator","+886-2-23123456","#62910",{"name":108,"role":38,"phone":10,"phoneExt":10,"email":10},"Jin-Yuan Shih, Medicine",{"facility":110,"status":21,"city":85,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"Taipei Veteran General Hospital",{"type":26,"coordinates":112},[88,89],{"lat":89,"lon":88},[115,119],{"name":116,"role":15,"phone":117,"phoneExt":118,"email":10},"Ping-Ju Study Coordinator","+886-2-2871-2121","#82872",{"name":120,"role":38,"phone":10,"phoneExt":10,"email":10},"Chien-Sheng Huang, Medicine",{"facility":122,"status":21,"city":123,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Chang Gung Memorial Hospital Linkou Branch","Taoyuan",{"type":26,"coordinates":125},[126,127],121.29696,24.99368,{"lat":127,"lon":126},[130,132],{"name":131,"role":15,"phone":10,"phoneExt":10,"email":10},"Wen Study Coordinator",{"name":133,"role":38,"phone":10,"phoneExt":10,"email":10},"Cheng-Ta Yang, Medicine",{"type":135,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[137],{"name":138,"class":6},"Bristol-Myers Squibb","100605989","a-retrospective-observational-study-of-nivolumab-in-combination-with-chemotherapy-as-neoadjuvant-therapy-for-resectable-nsclc-patients-real-world-experience-in-taiwan-neoreal-100605989",false,"NCT07169708","A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)","A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan","Inclusion Criteria:\n\n1. Aged 18 years and older\n2. Patients who are diagnosed with pathologically confirmed, non-metastatic, resectable NSCLC\n3. Patients who have received at least one cycle of neoadjuvant nivolumab combined with chemotherapy since the approval of the regimen in February 2023, and who have at least one imaging assessment of EFS and surgical status recorded. For patients who underwent surgery, at least one pathological report is required.\n4. Patients who have been followed up for at least 12 months (from first dose of neoadjuvant therapy to last medical record date at study site), exceptional case as follows:\n\n   * Patients who expired within 12 months of follow-up\n   * Patients who experience disease progression or recurrence but continue to follow-up\n5. Participants with histologically confirmed Stage II-III NSCLC (per the 8th International Association for the Study of Lung Cancer) who are considered resectable.\n\nExclusion Criteria:\n\n1. Patients with distant metastasis (M1 disease according to the eighth edition of the American Joint Committee on Cancer \\[AJCC\\] cancer staging manual) prior to neoadjuvant therapy\n2. Patients with N3 disease per AJCC 8th edition\n3. Patients with known EGFR mutations or ALK translocation\n4. Patients who have received any prior systemic therapy for NSCLC\n5. Patients with a history of previous cancers or other concurrent malignancies within 10 years before the first dose of nivolumab","ALL","18 Years",{"count":149,"type":150},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the effectiveness of Nivolumab in combination with chemotherapy as Neoadjuvant therapy for patients with non-small cell lung cancer (NSCLC). The main question it aims to answer is:\n\nDoes patient with NSCLC in treatment of Nivolumab combined with chemotherapy demonstrate better pCR and PFS ? Is it safe for patient with NSCLC in treatment of Nivolumab combined with chemotherapy ?\n\nThe data for those participants already receiving nivolumab in combination with chemotherapy as part of their regular medical care for NSCLC will be collected within the designated collection period.",[154],"Non Small Cell Lung Cancer NSCLC",[156,157,158,159,160],"NeoReal","NSCLC","Nivolumab","Opdivo","Neoadjuvant therapy","2026-05-18",{"date":163,"type":164},"2026-05-20","ACTUAL",{"date":166,"type":164},"2026-03-20",{"date":168,"type":150},"2026-06-30",{"name":5,"class":6},9]